What are the new drugs for Peripheral Artery Disease?

Overview of Peripheral Artery Disease

Peripheral artery disease (PAD) is a common and progressive atherosclerotic condition characterized by narrowing or occlusion of arteries – most notably those supplying the lower extremities. Patients with PAD often present with intermittent claudication (pain in the legs during exercise that is relieved by rest), rest pain in more advanced stages, and, in its most severe form, critical limb ischemia that may lead to tissue loss or the need for amputation. Patients may also experience numbness, weakness, and in some cases, non-healing wounds that are difficult to manage. The underlying pathology is an imbalance between the limited blood supply and the metabolic demands of lower limb tissues, which is compounded by associated risk factors such as smoking, diabetes mellitus, hypertension, and hyperlipidemia. 

Current Treatment Landscape 
Historically, the management of PAD has relied on a combination of non-pharmacological and pharmacological strategies. Lifestyle modifications – including smoking cessation, supervised exercise programs, and dietary changes – form the cornerstone of initial management. The pharmacological approach traditionally includes antiplatelet agents (such as aspirin and clopidogrel) to reduce the risk of cardiovascular events, statins for lipid control, and management of blood pressure and diabetes. In selected cases, revascularization (by percutaneous or surgical methods) is required to restore blood flow to ischemic tissues. However, despite these established measures, there is still a significant residual cardiovascular risk, and many patients continue to experience major adverse cardiovascular events (MACE) and progressive limb ischemia, which has driven the quest for newer and more targeted therapies.


Recent Pharmaceutical Developments

Newly Approved Drugs 
Recent years have witnessed an evolution from the “one‐size‐fits‐all” paradigm toward more tailored therapies addressing both thrombotic and inflammatory aspects of PAD. One of the most promising developments is the combination therapy of low‐dose rivaroxaban with aspirin. Rivaroxaban, a direct oral anticoagulant that acts as a factor Xa inhibitor, when used in low doses in tandem with aspirin, has been demonstrated to reduce cardiovascular events in patients with atherosclerotic conditions, including PAD. This combination has received approval in several regions as clinical studies have shown that adding low‐dose rivaroxaban to aspirin therapy can decrease the rate of MACE and the risk of limb amputation while maintaining an acceptable safety profile, especially when bleeding events are carefully monitored. 

In addition to antithrombotic strategies, several other drug candidates with unique mechanisms have been evaluated. For example, bosentan—a potent endothelin receptor antagonist that was originally approved for pulmonary arterial hypertension—has been repurposed in clinical explorations to improve blood flow in PAD by counteracting endothelin-1 mediated vasoconstriction. Vorapaxar, a protease-activated receptor-1 (PAR-1) antagonist, has also attracted attention as a novel antiplatelet agent for PAD. It works by inhibiting thrombin-induced platelet activation, although its use has been tempered by concerns about an increased risk of bleeding complications. Moreover, sildenafil—a phosphodiesterase type 5 inhibitor originally developed for erectile dysfunction—has been investigated for its vasodilatory effects in PAD. By enhancing nitric oxide–mediated vasodilation, sildenafil helps improve perfusion to ischemic tissues, offering an innovative approach beyond traditional antithrombotic therapy.

Drugs in Clinical Trials 
Beyond the newly approved combination of low‐dose rivaroxaban with aspirin, several investigational drugs are undergoing clinical trials in the PAD population. Research is actively exploring gene therapy approaches, with agents such as plasmid vascular endothelial growth factor (pl-VEGF165) being investigated in phase III postmarketing surveillance studies; these agents are aimed at promoting therapeutic angiogenesis to stimulate the formation of new blood vessels in ischemic limbs. 

Other promising candidates in the clinical trial pipeline include novel antiplatelet combinations that involve newer agents such as ticagrelor in combination with aspirin. Ticagrelor’s reversible inhibition of the P2Y12 receptor offers a distinct pharmacological profile compared with traditional, irreversible inhibitors like clopidogrel. Studies have evaluated the combination of ticagrelor plus aspirin and have noted significant reductions in composite cardiovascular endpoints in PAD patients, although these combinations must be carefully balanced against the risk of bleeding. 

There is also ongoing research into the repositioning of existing drugs for new indications in PAD. For example, sildenafil is currently under investigation not only because of its known vasodilatory properties but also due to its potential to improve endothelial function and reduce inflammatory cytokine production. In addition, studies with bosentan continue to assess its efficacy in improving limb perfusion by blocking the vasoconstrictive effects of endothelin-1, which could translate into clinical benefits such as improved walking distance and reduced claudication symptoms. 

Recent clinical trials are also focusing on regenerative and cell-based therapies. Although this area is still emerging, trials incorporating gene therapy and novel angiogenic factors represent a bold step toward addressing the underlying ischemia, rather than merely treating its consequences. These novel approaches are designed with the goal of revascularizing ischemic tissues, potentially reducing the need for surgical interventions and improving quality of life in PAD patients.


Mechanisms of Action

How New Drugs Work 
The new drugs for PAD leverage advanced mechanisms that target both thrombosis and the vascular dysfunction inherent in atherosclerosis. The low-dose rivaroxaban plus aspirin therapy, for instance, combines the antithrombotic benefits of aspirin with the anticoagulant effects of rivaroxaban. Rivaroxaban selectively inhibits factor Xa, reducing thrombin generation and subsequent fibrin clot formation, while aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) in platelets, thus decreasing thromboxane A₂ production and platelet aggregation. This dual mechanism not only minimizes the likelihood of clot formation but also addresses the diffuse microvascular thrombosis that can exacerbate ischemia in PAD. 

Bosentan works through a different pathway by blocking endothelin receptors (ET_A and, to some extent, ET_B) on vascular smooth muscle cells. Endothelin-1 is a potent vasoconstrictor and is often elevated in patients with vascular pathologies. By antagonizing these receptors, bosentan induces vasodilation, reducing vascular resistance and potentially improving blood flow to ischemic tissues. 

Vorapaxar, on the other hand, represents an advanced approach to antiplatelet therapy. It acts as a PAR-1 antagonist, effectively inhibiting thrombin-mediated platelet activation—a critical pathway in thrombus propagation. This mechanism is particularly attractive in PAD because the activation of platelets by thrombin is a key driver of plaque thrombogenicity, but its use can be limited by a narrow therapeutic window due to the risk of serious bleeding events. 

Sildenafil’s mechanism in PAD is primarily through inhibition of phosphodiesterase type 5 (PDE5). By blocking the degradation of cyclic guanosine monophosphate (cGMP), sildenafil enhances nitric oxide-mediated vasodilation. This not only improves blood flow but may also contribute to a reduction in inflammation and improvement of endothelial function in patients with PAD.

Finally, innovative gene therapies and angiogenic factors such as pl-VEGF165 work by directly stimulating the formation of new blood vessels—a process known as therapeutic angiogenesis. By upregulating vascular endothelial growth factor (VEGF) in ischemic tissues, these therapies aim to promote collateral circulation and restore perfusion to areas that are otherwise deprived of adequate blood supply.

Comparison with Existing Therapies 
Traditional therapies for PAD, such as aspirin monotherapy or clopidogrel, primarily focus on platelet inhibition and have been effective in reducing cardiovascular events. However, these single-mechanism agents do not fully address the multifactorial nature of PAD, where both thrombosis and vascular dysfunction play significant roles. The new drugs and combinations aim to fill this therapeutic gap. For example, the combination of low‐dose rivaroxaban with aspirin not only targets platelet aggregation but also coagulation pathways, offering broader antithrombotic protection compared with aspirin alone. 

Furthermore, while existing drugs tend to exhibit a singular mechanism of action, the newer agents incorporate both antithrombotic and vasodilatory or even angiogenic properties—thereby potentially offering benefits in terms of reducing claudication symptoms, ameliorating ischemia directly, and even promoting tissue repair through enhanced blood vessel growth. In contrast, drugs such as bosentan and sildenafil offer benefits via vascular modulation rather than direct antithrombotic effects, which could complement the actions of traditional agents while offering a novel approach to symptom relief. 

Additionally, novel antiplatelet agents like vorapaxar, although not without safety concerns, extend the current antiplatelet armamentarium by inhibiting different activation pathways in platelets. This diversification of targets can be particularly beneficial for patients who are refractory or intolerant to traditional therapies, despite the inherent trade-off with bleeding risks that remain a critical point of consideration.


Clinical Efficacy and Safety

Clinical Trial Outcomes 
Clinical trials evaluating these new pharmacotherapies for PAD have produced promising outcomes that offer hope for improved patient care. For example, the combination of low‐dose rivaroxaban with aspirin has been evaluated in large-scale outpatient trials, where it demonstrated a significant reduction in major adverse cardiovascular events (MACE) compared with aspirin monotherapy. The data suggest that this combination not only lowers the risk of thrombotic events but may also reduce the incidence of limb amputations by improving downstream microvascular perfusion. 

Trials of bosentan in PAD patients have explored the potential of endothelin receptor blockade to improve walking distance and reduce the severity of claudication. Although the data are less mature compared with established antithrombotic strategies, early-phase studies indicate that bosentan can produce measurable improvements in blood flow to ischemic tissues, translating into functional benefits. Similarly, early clinical evaluations of vorapaxar have shown that while it can reduce the risk of ischemic events, its use must be cautiously balanced against a higher incidence of bleeding complications. 

Sildenafil has also been examined in clinical studies as an adjunct to standard care for PAD. Its ability to promote vasodilation has been correlated with improved exercise tolerance and reduced ischemic pain. Importantly, the beneficial effects of sildenafil on endothelial function have been associated with favorable changes in biomarkers of vascular health in randomized studies, although long-term outcomes regarding limb preservation remain under investigation. 

Gene therapy approaches with agents like pl-VEGF165 have reached the postmarketing phase in some locales. In these studies, the primary endpoints typically focus on improvements in perfusion metrics and pain-free walking distance. The outcomes have been encouraging, with a significant number of patients experiencing increased collateral vessel formation and a corresponding improvement in functional capacity. However, there remains a need for longer-term data to confirm the durability of these benefits and to assess if they translate into reductions in limb loss or overall mortality.

Side Effects and Safety Profiles 
One of the overarching challenges with these innovative agents is their safety profile, particularly regarding bleeding risk and off-target effects. The combination of low‐dose rivaroxaban with aspirin, for instance, does result in an increased bleeding risk compared with aspirin alone; however, when the dose of rivaroxaban is carefully controlled, many studies have demonstrated that the overall benefit in reducing thrombotic events outweighs the bleeding complications. Each patient’s bleeding risk must be carefully evaluated, particularly in the elderly or those with a history of gastrointestinal bleeding. 

Bosentan is generally well tolerated in the context of pulmonary arterial hypertension, but its use in PAD must be reviewed carefully as liver function abnormalities and peripheral edema have been noted in some studies. Nonetheless, in the PAD population these side effects appear to be manageable with appropriate monitoring. 

Vorapaxar has shown a distinct safety concern: although its antithrombotic efficacy is notable, clinical trials have consistently indicated an increased risk of serious bleeding events, including intracranial hemorrhage. As a result, its use is often restricted to carefully selected patient groups and may require stringent monitoring protocols. 

Sildenafil’s safety profile has been well established in other indications, like erectile dysfunction and pulmonary hypertension. In PAD trials, the most common adverse effects reported include headaches, flushing, and dyspepsia. These side effects are generally mild or moderate in intensity; however, the long-term cardiovascular safety in the context of chronic use for PAD requires further elucidation. 

For gene therapy approaches such as pl-VEGF165, the safety evaluation is even more complex. Aside from the technical challenges related to gene delivery, potential concerns include immune reactions, off-target effects, and the durability of angiogenic responses. Fortunately, early data indicate that these therapies can be administered with an acceptable safety margin, although robust, long-term surveillance studies remain essential.


Future Directions and Challenges

Ongoing Research 
The development of new drugs for PAD is a rapidly evolving field where current research efforts span from further optimization of combination antithrombotic regimens to entirely novel approaches—including gene and cell-based therapies. Ongoing clinical trials are continuing to evaluate the efficacy of low‐dose rivaroxaban and aspirin in broader PAD populations, potentially expanding their use to patients with less symptomatic disease. Concurrently, late-stage trials investigating novel antiplatelet agents such as ticagrelor in combination regimens indicate that there may be additional benefit in subsets of patients who are at particularly high ischemic risk. 

In parallel, extensive research is underway to refine the use of repurposed drugs. For instance, studies with bosentan are exploring its role not only in improving vascular tone but also in modulating inflammatory pathways that contribute to atherosclerotic progression. Research with sildenafil continues to investigate its potential benefits on endothelial function and its possible synergistic effects when used alongside other vasoactive medications. 

Beyond these pharmacologic agents, the field of vascular regenerative medicine is a frontier with enormous potential. Trials of angiogenic gene therapies, using agents like pl-VEGF165, represent a paradigm shift in PAD treatment. These therapies are designed to promote neovascularization in chronically ischemic limbs, offering the possibility of restoring blood flow in cases where conventional revascularization techniques are not feasible. Additionally, there is growing interest in combining traditional pharmacotherapy with regenerative approaches to achieve additive or synergistic effects that could radically improve functional outcomes in PAD patients.

Challenges in Drug Development for PAD 
Despite the promising advances, drug development for PAD faces several significant challenges. One major issue is the heterogeneity of the PAD patient population. Patients differ widely with respect to the severity of disease, the presence of comorbid conditions (such as diabetes and chronic kidney disease), and varying responses to therapy. These factors complicate the design and interpretation of clinical trials, as endpoints such as pain-free walking distance and rates of limb amputation may be influenced by multiple variables unrelated to the efficacy of the drug itself. 

Another challenge is balancing efficacy with safety. For example, while combination therapies like low‐dose rivaroxaban plus aspirin have demonstrated robust efficacy in reducing thrombotic events, the concurrent risk of bleeding — a common concern in antithrombotic therapies — must be strictly managed. This necessitates careful patient selection and rigorous postmarketing surveillance to ensure that the benefits of therapy continue to outweigh potential harms. 

Furthermore, the development of drugs such as vorapaxar has underscored the difficulties associated with targeting novel pathways. Although the inhibition of PAR-1 offers a promising mechanism to reduce platelet activation, the consistently observed higher rates of bleeding have led to a cautious approach regarding its widespread use in PAD. This highlights the importance of comprehensive safety evaluations throughout drug development and the need for personalized medicine approaches that might help identify patients who could benefit from these therapies with minimal risk. 

From a regulatory perspective, the complexity of PAD as a disease and the need for composite endpoints (which often include both cardiovascular events and limb-specific outcomes) require robust clinical trial designs that can withstand scrutiny. Many trials have had to rely on surrogate endpoints such as changes in perfusion or walking distance rather than hard endpoints like mortality or amputation rates, which in turn adds uncertainty regarding the long-term clinical benefits of the new drugs. 

Finally, the integration of innovative therapeutic approaches such as gene therapy into standard care presents added layers of scientific, logistical, and ethical challenges. The long-term safety profile of gene therapies remains uncertain, and issues such as immune responses, optimal dosing, and delivery methods require further investigation before these can be considered mainstream treatments for PAD.

Detailed and Explicit Conclusion 
In summary, the landscape of new drugs for peripheral artery disease is rapidly expanding as researchers and clinicians seek to address the residual cardiovascular and limb risk that persists despite traditional therapies. The combination of low‐dose rivaroxaban with aspirin represents one of the most significant recent approvals, offering a dual antithrombotic mechanism that effectively reduces major adverse cardiovascular events and potentially lowers the risk of limb loss. Repurposed drugs such as bosentan, vorapaxar, and sildenafil provide new approaches targeting vascular tone, platelet activation, and endothelial dysfunction, respectively. 

Clinical trials have demonstrated promising outcomes with these therapies, yet safety concerns remain, particularly with respect to bleeding risks associated with potent antithrombotic agents like vorapaxar. Meanwhile, ongoing research in gene and cell-based therapies—such as the use of pl-VEGF165 to induce therapeutic angiogenesis—holds the potential to fundamentally alter the management paradigm of PAD by directly addressing ischemia at the tissue level. 

Comparatively, the new drugs work through multifaceted mechanisms that contrast with traditional monotherapies; they not only inhibit thrombosis but also improve blood flow via vasodilation and promote vascular regeneration. Although these novel therapies hold promise, challenges remain in balancing efficacy with safety, managing patient heterogeneity, and designing clinical trials with robust, clinically meaningful endpoints. The advancement of these drugs will depend on continued research efforts, improved trial designs, and enhanced monitoring strategies to minimize adverse events while maximizing clinical benefits. 

In conclusion, the future of pharmacotherapy in PAD is moving toward multi-targeted strategies that combine antithrombotic, vasodilatory, and regenerative elements. This evolution is expected to yield new drug formulations and combination regimens that can provide substantial improvements in both cardiovascular outcomes and limb preservation. However, rigorous clinical testing and meticulous postmarketing surveillance will be critical to ensure that these therapies achieve their full potential in the management of PAD, ultimately leading to a significant improvement in the quality of life for patients suffering from this debilitating disease.

For an experience with the large-scale biopharmaceutical model Hiro-LS, please click here for a quick and free trial of its features！